We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Onzima Ventures | LSE:ONZ | London | Ordinary Share | GB00BYQCDH57 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Onzima Ventures plc
("Onzima" or the "Company")
Investee company N4 Pharma announces latest research results for Nuvec®
Change of registered office
N4 Pharma Limited (“N4 Pharma”), in which Onzima holds a 49% equity stake, has announced that it has successfully demonstrated in-vitro transfection efficiency for its Nuvec® DNA vaccine system comparable to industry standard transfection reagents.
Its latest results show that optimised Nuvec® particles achieved 80-90% transfection efficiency in HEK 293 cells, the same levels as Lipofectamine 2000.
These results can be found here: http://www.n4pharma.co.uk/download/i/mark_dl/u/4013008883/4630405716/nuvec%20dna%20transfection%20results%201.pdf
N4 Pharma CEO Nigel Theobald commented:
“Our research on our Nuvec® particles continues to show impressive results. Lipofectamine is widely used for DNA transfection experiments as it achieves high levels of in-vitro transfection efficiency however it has been demonstrated to have negative toxic effects on cells so is not used in commercial product development for in-vivo administration.
We are continuing to build our evidence on Nuvec towards establishing its acceptability as an in-vivo delivery vector for DNA and RNA based vaccines. Our next steps are to compare the toxicity of Nuvec® with lipofectamine® where we expect to show markedly lower toxicity of our particles making them more suitable for in-vivo use.
We are clearly able to demonstrate high transfection levels, which opens up the potential for longer term use of Nuvec® as an in-vivo transfection agent for DNA vaccines. Our R&D program is designed step by step to build the supporting case for this application for the nuvec® system.
This latest data represents strong steady progress on the path towards commercialisation of Nuvec®. We expect further results comparing the toxicity and transfection efficiency of Nuvec® against a wider range of existing transfection agents in a range of different cell types, over the next 3 or 4 months including comparison against those vectors already established for in-vivo use. ”
The Company also announces that its registered office has now changed to 6th Floor, 60 Gracechurch Street, London EC3V 0HR.
For further information please contact:
Onzima Ventures PLC Tel: +44 (0) 1732 366 561
Gavin Burnell, Luke Cairns
Nominated Adviser
Cairn Financial Advisers LLP Tel: +44 (0) 20 7 213 0880
Sandy Jamieson, Liam Murray
Broker
Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930
Guy Miller, Lucy Williams
Copyright r 11 PR Newswire
1 Year Onzima Ventures Chart |
1 Month Onzima Ventures Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions